ClinicalTrials.gov
ClinicalTrials.gov Menu

Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00316576
Recruitment Status : Terminated (The study was stopped on november 2006 after inclusion was fulfilled)
First Posted : April 21, 2006
Last Update Posted : January 17, 2008
Sponsor:
Information provided by:
University Hospital, Caen

Brief Summary:
Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Condition or disease Intervention/treatment
Kidney Failure, Acute Critical Illness Procedure: Blood sampling for PCR

Detailed Description:
Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

Study Type : Observational
Estimated Enrollment : 160 participants
Time Perspective: Prospective
Official Title: Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients
Study Start Date : May 2006
Actual Study Completion Date : November 2006



Primary Outcome Measures :
  1. Incidence of ARF [ Time Frame: During ICU stay ]

Secondary Outcome Measures :
  1. Mortality [ Time Frame: ICU and Hospital mortality ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Consecutive patients admitted to ICU fore more than 48 hours
Criteria

Inclusion Criteria:

  • Age > 18 yrs
  • ICU stay > 48 hours

Exclusion Criteria:

  • Age < 18 yrs
  • Creatinine > 180 µmol/L
  • Absence of consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00316576


Locations
France
Medical Intensive care Unit; Caen University Hospital
Caen, France, 14000
Sponsors and Collaborators
University Hospital, Caen
Investigators
Principal Investigator: Damien du Cheyron, MD University Hospital, Caen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00316576     History of Changes
Other Study ID Numbers: 05-130
First Posted: April 21, 2006    Key Record Dates
Last Update Posted: January 17, 2008
Last Verified: January 2008

Keywords provided by University Hospital, Caen:
Kidney failure, Acute
Genetic Polymorphism
Angiotensin-converting enzyme

Additional relevant MeSH terms:
Renal Insufficiency
Critical Illness
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Disease Attributes
Pathologic Processes